Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru
We evaluated neutralizing antibody (NAbs) levels as a protective factor against vaccine breakthrough infection (VBI) in healthcare workers (HCWs) during the third COVID-19 wave in Peru. This retrospective cohort study employed the information from a private laboratory in Lima (Peru) of HCW who recei...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/2/447 |
| _version_ | 1797617847092903936 |
|---|---|
| author | Miguel Hueda-Zavaleta Juan C. Gómez de la Torre José Alonso Cáceres-DelAguila Cecilia Muro-Rojo Nathalia De La Cruz-Escurra Cesar Copaja-Corzo Carlos J. Aragón-Ayala Vicente A. Benítes-Zapata |
| author_facet | Miguel Hueda-Zavaleta Juan C. Gómez de la Torre José Alonso Cáceres-DelAguila Cecilia Muro-Rojo Nathalia De La Cruz-Escurra Cesar Copaja-Corzo Carlos J. Aragón-Ayala Vicente A. Benítes-Zapata |
| author_sort | Miguel Hueda-Zavaleta |
| collection | DOAJ |
| description | We evaluated neutralizing antibody (NAbs) levels as a protective factor against vaccine breakthrough infection (VBI) in healthcare workers (HCWs) during the third COVID-19 wave in Peru. This retrospective cohort study employed the information from a private laboratory in Lima (Peru) of HCW who received only two BBIBP-CorV vaccines or (additionally) a heterologous booster with BNT162b2. We evaluated the association between the VBI and the levels of NAbs at 21, 90, 180, and 210 days after the BBIBP-CorV second dose. NAbs were calculated with the cPass™ SARS-CoV-2 Neutralization Antibody Detection kit (surrogate virus neutralization test (sVNT)) and the Elecsys<sup>®</sup> anti-SARS-CoV-2 S Test. Of the 435 HCW evaluated, 31.72% had an infection previous to vaccination, 68.28% received a booster dose, and 23.21% had a VBI during the third wave. The variables associated with a lower risk of VBI were male sex (aRR: 0.43) and those who had (180 days after BBIBP-CorV inoculation) NAbs levels ≥ 60% (aRR: 0.58) and ≥90% (aRR: 0.59) on cPass™, and ≥500 with Elecsys<sup>®</sup> (aRR: 0.58). HCW whose NAbs persisted at higher levels six months after the BBIBP-CorV showed a lower risk of suffering from a VBI during the third COVID-19 wave. |
| first_indexed | 2024-03-11T08:01:37Z |
| format | Article |
| id | doaj.art-5f09016a45e944d0b6e546ef6eb6578b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T08:01:37Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-5f09016a45e944d0b6e546ef6eb6578b2023-11-16T23:44:32ZengMDPI AGVaccines2076-393X2023-02-0111244710.3390/vaccines11020447Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in PeruMiguel Hueda-Zavaleta0Juan C. Gómez de la Torre1José Alonso Cáceres-DelAguila2Cecilia Muro-Rojo3Nathalia De La Cruz-Escurra4Cesar Copaja-Corzo5Carlos J. Aragón-Ayala6Vicente A. Benítes-Zapata7Facultad de Ciencias de la Salud, Universidad Privada de Tacna, Tacna 23003, PeruRoe Clinical Laboratory, Lima 15076, PeruRoe Clinical Laboratory, Lima 15076, PeruRoe Clinical Laboratory, Lima 15076, PeruRoe Clinical Laboratory, Lima 15076, PeruFacultad de Ciencias de la Salud, Universidad Científica del Sur, Lima 15842, PeruFacultad de Medicina, Universidad Nacional de San Agustin de Arequipa, Arequipa 04000, PeruUnidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima 15024, PeruWe evaluated neutralizing antibody (NAbs) levels as a protective factor against vaccine breakthrough infection (VBI) in healthcare workers (HCWs) during the third COVID-19 wave in Peru. This retrospective cohort study employed the information from a private laboratory in Lima (Peru) of HCW who received only two BBIBP-CorV vaccines or (additionally) a heterologous booster with BNT162b2. We evaluated the association between the VBI and the levels of NAbs at 21, 90, 180, and 210 days after the BBIBP-CorV second dose. NAbs were calculated with the cPass™ SARS-CoV-2 Neutralization Antibody Detection kit (surrogate virus neutralization test (sVNT)) and the Elecsys<sup>®</sup> anti-SARS-CoV-2 S Test. Of the 435 HCW evaluated, 31.72% had an infection previous to vaccination, 68.28% received a booster dose, and 23.21% had a VBI during the third wave. The variables associated with a lower risk of VBI were male sex (aRR: 0.43) and those who had (180 days after BBIBP-CorV inoculation) NAbs levels ≥ 60% (aRR: 0.58) and ≥90% (aRR: 0.59) on cPass™, and ≥500 with Elecsys<sup>®</sup> (aRR: 0.58). HCW whose NAbs persisted at higher levels six months after the BBIBP-CorV showed a lower risk of suffering from a VBI during the third COVID-19 wave.https://www.mdpi.com/2076-393X/11/2/447COVID-19SARS-CoV-2vaccine breakthrough infectionhumoral immunityheterologous booster vaccineneutralizing antibody |
| spellingShingle | Miguel Hueda-Zavaleta Juan C. Gómez de la Torre José Alonso Cáceres-DelAguila Cecilia Muro-Rojo Nathalia De La Cruz-Escurra Cesar Copaja-Corzo Carlos J. Aragón-Ayala Vicente A. Benítes-Zapata Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru Vaccines COVID-19 SARS-CoV-2 vaccine breakthrough infection humoral immunity heterologous booster vaccine neutralizing antibody |
| title | Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru |
| title_full | Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru |
| title_fullStr | Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru |
| title_full_unstemmed | Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru |
| title_short | Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru |
| title_sort | neutralizing antibodies as predictors of vaccine breakthrough infection in healthcare workers vaccinated with or without a heterologous booster dose a cohort study during the third covid 19 wave in peru |
| topic | COVID-19 SARS-CoV-2 vaccine breakthrough infection humoral immunity heterologous booster vaccine neutralizing antibody |
| url | https://www.mdpi.com/2076-393X/11/2/447 |
| work_keys_str_mv | AT miguelhuedazavaleta neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu AT juancgomezdelatorre neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu AT josealonsocaceresdelaguila neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu AT ceciliamurorojo neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu AT nathaliadelacruzescurra neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu AT cesarcopajacorzo neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu AT carlosjaragonayala neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu AT vicenteabeniteszapata neutralizingantibodiesaspredictorsofvaccinebreakthroughinfectioninhealthcareworkersvaccinatedwithorwithoutaheterologousboosterdoseacohortstudyduringthethirdcovid19waveinperu |